According to the TechSci Research report titled “In Situ Hybridization Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F,” the Global In Situ Hybridization market is poised to experience substantial growth during the forecast period of 2024-2028. This growth can be attributed to the increasing adoption of in situ hybridization products for managing genetic disorders and cancer patients, alongside a growing demand for quality medical care across the region. Furthermore, factors such as healthcare spending, rising government initiatives in proteomics and genomics research, and increasing awareness about the use of tissue diagnostic tests are key drivers of market expansion in this projected timeframe. Additionally, the rise in initiatives by market players, including partnerships, mergers, and acquisitions for in situ hybridization techniques, is expected to further augment growth in the global In Situ Hybridization market. Moreover, governments across the world are providing support for healthcare industry development, including funding for research and development, which is anticipated to drive demand for the In Situ Hybridization market throughout the forecast period.
However, the high cost associated with In Situ Hybridization could potentially hinder the growth of the global In Situ Hybridization market during the forecast period. Moreover, in situ hybridization is a complex technique that requires specialized expertise and training for both execution and result interpretation. The intricacy of the technique may pose challenges for some researchers and clinicians when it comes to adopting and incorporating it into their workflows. Similarly, limited sensitivity, availability of alternative techniques such as Polymerase Chain Reaction and Next Generation Sequencing that provide comparable or complementary information, may be more widely adopted or preferred by some researchers and clinicians. This could potentially impede the market’s growth in the forecast period.
Browse over XX market data Figures spread through xx Pages and an in-depth TOC on “Global In Situ Hybridization Market” – https://www.techsciresearch.com/report/in-situ-hybridization-market/15520.html
The In Situ Hybridization market can be categorized based on product, technology, application, end-user, and region. With regards to technology, the global In Situ Hybridization market can be further divided into fluorescent in situ hybridization versus chromogenic in situ hybridization. The fluorescent in situ hybridization segment dominated the market in 2022 and is projected to continue maintaining its dominance throughout the forecast period. This can be attributed to the increased use of this technique in diagnostic laboratories for cancer diagnosis and research, as well as in the diagnosis of genetic disorders, infectious diseases, and other conditions. Furthermore, the adoption of Fluorescence In Situ Hybridization (FISH) in clinical diagnostics and research applications is on the rise, leading to expected lucrative growth during the forecast period.
In terms of application, the market is further segmented into cancer diagnostics, cytology, infectious diseases diagnostics, neuroscience, and immunology. The Cancer Diagnostics segment is expected to dominate during the forecast period due to the high demand for Fluorescence In Situ Hybridization in detecting cellular and genetic markers in cancers such as HER2, ALK, and ROS, along with the increasing adoption of personalized medicine and targeted therapies.
Major companies operating in the global In Situ Hybridization market are:
- Abbott Laboratories
- F.Hoffmann Roche AG.
- Thermo Fisher Scientific Inc.
- Danaher Corp.
- Agilent Technologies Inc.
- Biocare Medical LLC.
- Biotechne Corporation.
- Qiagen N.V
- Merck KGAA.
- Perkinelmer Inc
Recent Development
- On July 7, 2021, Thermo Fisher Scientific and Ortho Clinical Diagnostics announced a partnership to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers.
- Sysmex Corporation announced the signing of a Global Business Partnership Agreement with Roche Diagnostics International Ltd., the diagnostic reagent business unit of F. Hoffmann-La Roche, Ltd., on December 14, 2020.
- In July 2021, Merck entered into immuno-oncology collaboration agreements with GlaxoSmithKline plc (GSK) in the United Kingdom and Pfizer Inc. (Pfizer) in the United States.
- In March 2020, Agilent Technologies Inc. announced the completion of its acquisition of BioTek Instruments, a global leader in the design, manufacture, and distribution of cutting-edge life science instrumentation.
- In March 2021, Thermo Fisher Scientific Inc., a global leader in science service, announced the release of the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to provide rapid and highly reliable insight into the presence of in-air pathogens such as SARS-CoV-2.
Customers can also request for 10% free customization on this report.
“North America is expected to dominate in the global In Situ Hybridization market owing to the increase in funding for the development of research and healthcare infrastructure and a rise in biomedical research activities across the region. Similarly, increasing incidence of cancer and infectious diseases and growing demand for personalized medicine is expected to create lucrative growth in the market during the forecast period. Moreover, strong demand for early cancer detection capabilities and rise in awareness among patients, and a surge in per capita expenditure are expected to drive the growth of the market during the forecast period. Furthermore, increasing occurrence of genetic disease and disorder and growing demand for personalized testing kits is further expected to create lucrative opportunities for market growth,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“In Situ Hybridization Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” Segmented By Product (Consumables, Instruments, Software), By Technology (Fluorescent in situ hybridization v/s Chromogenic in situ hybridization), By Application (Cancer Diagnostics, Cytology, Infectious Diseases Diagnostics, Neuroscience, Immunology), By End User (Hospitals and Diagnostic laboratories, Academic & Research institutes, Pharmaceutical & Biotechnology companies, Contract Research Organizations), By Region and By Competition”, has evaluated the future growth potential of global In Situ Hybridization market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision-makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the global In Situ Hybridization market.
Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=15520
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
